Abstract:Purpose: Myelodysplastic syndromes (MDS), is characterized by clinical heterogeneity and varying prognoses. Reliable prognostic models are essential to stratify MDS patients and optimize clinical management. Although incorporating molecular information into MDS prognostic models improves their predictive ability, limitations of next-generation sequencing panels and potential heterogeneity among MDS patients with different karyotypes hinder their clinical translation. Methods: In total, 237 normal karyotype (NK) MDS patients from the First Affiliated Hospital of Zhejiang University School of Medicine were used as the derivation set to investigate the molecular frequency and prognostic spectrum. A parsimonious molecular-clinical model was developed with overall survival (OS) as the endpoint and compared with other models using the concordance index as the primary evaluation index. An external independent validation set from the International Working Group for Prognosis in MDS cohort(691 NK MDS patients) was used to evaluate the model generalization ability. Results: In NK MDS, the gene mutation frequency spectrum is similar to the overall MDS population, the differences mainly lie in the prognostic spectrum. Genes such as TP53, previously associated with MDS prognoses have lost their prognostic value. Therefore, a seven-parameter molecular-clinical prognostic model called the Molecular Prognostic Scoring System for NK MDS (NK-PSS-M) was developed based on a specific molecular prognostic spectrum of NK MDS. The model includes age, hemoglobin, platelet count, blast percentage, CEBPA, RUNX1, and U2AF1. The NK-PSS-M model allows for personalized risk assessment based on patient characteristics, with higher scores indicating a greater risk and poorer prognosis. In addition, we developed a five-class classification system based on these scores, which differentiates patients across risk categories and predicts outcomes, such as OS and LFS(Figure 1 A and B). The performance of NK-PSS-M was comparable to that of the Molecular International Prognostic Scoring System(IPSS-M), and it significantly outperformed IPSS-R and other molecular prediction models based on it. The above results were confirmed in the external independent validation cohort(Figure 1C). Our transcriptomics analysis revealed that the low-risk group defined by NK-PSS-M demonstrated significant activation of the inflammatory pathway, and immune activation, which is consistent with the current understanding of the immunological landscape of MDS. Conclusion: The NK-PSS-M model improved the risk stratification of non-molecular models and provided a reliable alternative to the IPSS-M. In addition, we demonstrated the molecular heterogeneity of MDS across different cytogenetics and emphasized the importance of developing cytogenetics-specific prognostic models.

Prognosis in Myelodysplastic Syndromes: The Clinical Challenge of Genomic Integration

The Molecular Prognostic Scoring System for Normal Karyotype Myelodysplastic Syndromes

A Novel Prognostic Scoring Model for Myelodysplastic Syndrome Patients with SF3B1 Mutation.

Gene mutation patterns and their prognostic impact in a cohort of 1185 patients with acute myeloid leukemia

Clinical Significance of Cytogenetic and Molecular Genetic Abnormalities in 634 Chinese Patients with Myelodysplastic Syndromes

Mutation Status and Burden Can Improve Prognostic Prediction of Patients with Lower-Risk Myelodysplastic Syndromes.

Cytogenetic Abnormalities Predict Disease Progression in Primary Myelodysplastic Syndrome: A Multicentric Study in 508 Chinese Patients.

Diagnosis and Treatment of Myelodysplastic Syndrome in the Era of Genetic Testing

[Recent Advances of Molecular Mechanisms Influencing Prognosis of Myelodysplastic Syndrome - Review].

The Molecular Pathology of Myelodysplastic Syndrome

Classification and Personalized Prognostic Assessment on the Basis of Clinical and Genomic Features in Myelodysplastic Syndromes

Genome sequencing in the management of myelodysplastic syndromes and related disorders

The genetics of myelodysplastic syndromes and the opportunities for tailored treatments

Myelodysplastic Syndromes in the Postgenomic Era and Future Perspectives for Precision Medicine

Analysis of Mutations of 14 Genes among 87 Patients with Myelodysplastic Syndrome

Analysis of gene mutation characteristics and its correlation with prognosis in patients with myelodysplastic syndromes

Genomic Landscape Of Cd34(+) Hematopoietic Cells In Myelodysplastic Syndrome And Gene Mutation Profiles As Prognostic Markers

Configuration of the TP53 gene as an independent prognostic parameter of myelodysplastic syndrome

The molecular pathogenesis of myelodysplastic syndromes

Selecting appropriate therapy for lower-risk myelodysplastic syndromes: current state and future prospects

Personalized Risk Schemes and Machine Learning to Empower Genomic Prognostication Models in Myelodysplastic Syndromes